DFC, Biological E unveil plan to expand Covid vaccine manufacturing in India

The two sides finalize US govt plan formalizing $50 million to expand the company’s capacity to produce vaccines

DFC, Biological E unveil plan to expand Covid vaccine manufacturing in India
DFC, Biological E unveil plan to expand Covid vaccine manufacturing in India. Photograph by Rajeev Bhatt

US International Development Finance Corporation (DFC) COO David Marchick and Biological E. Limited Managing Director Mahima Datla on Monday unveiled the expansion of Biological E.’s vaccine manufacturing facility in Hyderabad and finalized a US government financing arrangement formalizing $50 million to expand the company’s capacity to produce Covid-19 vaccines.

The partnership will help bolster near-term Covid-19 response efforts and will also benefit long-term global health in India and throughout the Indo-Pacific region, a statement issued by DFC said.